Compare · MTD vs TBIO
MTD vs TBIO
Side-by-side comparison of Mettler-Toledo International Inc. (MTD) and Telesis Bio Inc. (TBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTD and TBIO operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- MTD carries a market cap of $33.93B.
- MTD has hit the wire 26 times in the past 4 weeks while TBIO has been quiet.
- MTD has more recent analyst coverage (25 ratings vs 4 for TBIO).
- Company
- Mettler-Toledo International Inc.
- Telesis Bio Inc.
- Price
- -
- -
- Market cap
- $33.93B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- 2021
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 4
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Telesis Bio Inc.
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
Latest MTD
- President and CEO Kaltenbach Patrick was granted 534 shares, increasing direct ownership by 11% to 5,510 units (SEC Form 4)
- Head of Process Analytics Keller Gerry was granted 62 shares, increasing direct ownership by 20% to 379 units (SEC Form 4)
- Chief Financial Officer Vadala Shawn was granted 176 shares, increasing direct ownership by 3% to 5,934 units (SEC Form 4)
- Head of PI, Retail, and GSC Wittorf Oliver was granted 51 shares, increasing direct ownership by 9% to 600 units (SEC Form 4)
- Head of Asia & Pacific Wong Ann Ping Richard was granted 64 shares, increasing direct ownership by 9% to 767 units (SEC Form 4)
- Director Salice Thomas P was granted 77 shares, increasing direct ownership by 26% to 369 units (SEC Form 4)
- Director Zhang Ingrid was granted 54 shares, increasing direct ownership by 26% to 261 units (SEC Form 4)
- Director Wienand Wolfgang was granted 54 shares, increasing direct ownership by 30% to 237 units (SEC Form 4)
- Director Tokich Michael J was granted 54 shares, increasing direct ownership by 108% to 104 units (SEC Form 4)
- Director Shuman-Fabbri Natalia was granted 54 shares, increasing direct ownership by 338% to 70 units (SEC Form 4)
Latest TBIO
- Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
- Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis
- SEC Form 15-12G filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.